Gossamer Bio, Inc. - GOSS

SEC Filings Our GOSS Tweets

About Gravity Analytica

Recent News

10.21.2026 - Leadership, Mentorship, and Professional Well-being in Pulmonary Hypertension: Insights From the Women’s PHorum Survey
10.20.2026 - Determinants of monotherapy use in pulmonary arterial hypertension and treatment patterns in mild disease: A contemporary real-world United States study
10.14.2026 - Comparative and Combined Effects of Seralutinib and Nintedanib Reveal Enhanced Anti-Fibrotic and Anti-Inflammatory Activity in Pulmonary Fibrosis Models
10.14.2026 - Targeted Kinase Inhibition with Seralutinib Attenuates Bleomycin-Induced Fibrosis in Contrast to Imatinib
09.08.2026 - Comparative and combined effects of seralutinib and nintedanib suggest synergistic anti-fibrotic and anti-inflammatory activity in IPF patient-derived lung models
09.08.2026 - Exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study
09.06.2026 - Effects of seralutinib on pulmonary vascular remodeling assessed by quantitative CT: A randomized, double-blind, placebo-controlled imaging substudy of the phase 3 PROSERA trial
09.06.2026 - Targeted genetic profiling of PAH-predisposing genes and exploratory seralutinib response by genotype in the phase 3 PROSERA study
06.12.2026 - For Patients: Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial
06.11.2026 - Understanding the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis

Gossamer Bio, Inc. - GOSS

About Gravity Analytica

Recent News

Recent Filings